Skip to main content
SpringerLink
Log in

Posaconazole

SCH 56592

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

Abstract

Posaconazole [SCH 56592, SPRIAFIL™, Noxafil™] is an orally active triazole derivative that is in phase III trials with the Schering-Plough Research Institute (SPRI) in the US for the treatment of serious opportunistic fungal infections, including aspergillosis, candidiasis, coccidioidomycosis and fusariosis.1

Preclinical studies have also been conducted in Italy for the potential treatment of Cryptococcus neoformans infection (cryptococcosis).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Thonoor M, Gupta S, Solon E. Pharmacokinetics of 14C-SCH 56592 in rats and dogs. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy: 18, 28 Sep 1997

  2. Ezzet F, Wexler D, Courtney R, et al. The pharmacokinetics of posaconazole in neutropenic oncology patients. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy: 4, 22 Sep 2001

  3. Hachem RY, Raad II, Afif CM, et al. An open, non-comparative multicenter study to evaluate efficacy and safety of posaconazole (SCH 56592) in the treatment of invasive fungal infections refractory to or intolerant to standard therapy. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy: 372 (plus poster), 17 Sep 2000

  4. Nieto L, Northland R, Pittisuttithum P, et al. Posaconazole equivalent to fluconazole in the treatment of oropharyngeal candidiasis. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy: 372, 17 Sep 2000

  5. Vazquez JA, Northland R, Miller S, et al. Posaconazole compared to fluconazole for oral candidiasis in HIV-positive patients. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy: 372, 17 Sep 2000

  6. Courtney RD, Statkevich P, Laughlin M, et al. Potential for a drug interaction between posaconazole and phenytoin. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy: 4, 22 Sep 2001

  7. Courtney RD, Statkevich P, Laughlin M, et al. Potential for a drug interaction between posaconazole and rifabutin. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy: 4–5, 22 Sep 2001

  8. Courtney RD, Statkevich P, Laughlin M, et al. Effect of posaconazole on the pharmacokinetics of cyclosporine. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy: 4, 22 Sep 2001

  9. Fung-Tomc JC, Bonner DP. Recent developments in pradimicin-benanomicin and triazole antibiotics. Expert Opinion on Investigational Drugs 6: 129–145, Feb 1997

    Article  PubMed  CAS  Google Scholar 

  10. Urbina JA, Payares G, Sanoja C. In vitro and in vivo antiproliferative effects of SCH 56592 against Trypanosoma cruzi, the causative agent of Chagas disease. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy: 117, 15 Sep 1996

  11. Graybill JR, Bocanegra R, Najvar LK, et al. SCH56592 treatment of murine invasive aspergillosis. Journal of Antimicrobial Chemotherapy 42: 539–542, Oct 1998

    Article  PubMed  CAS  Google Scholar 

  12. Espinel-Ingroff A. Comparison of the in vitro activities of voriconazole and other new triazoles with those of established agents. Clinical Microbiology and Infection 5 (Suppl. 3): 285–286, Mar 1999

    Google Scholar 

  13. Manavathu EK, Abraham OC, Cutright JL, et al. Isolation and in vitro susceptibility to amphotericin B, itraconazole and SCH56592 of voriconazole-resistant laboratory isolates of Aspergillus fumigatus. Ninety-Ninth General Meeting American Society for Microbiology: 14, 30 May 1999

  14. Manavathu EK, Cutright JL, Loebenberg D, et al. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus sp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). Journal of Antimicrobial Chemotherapy 46: 229-234, Aug 2000

    Article  PubMed  CAS  Google Scholar 

  15. Hayette MP, Amadore A, Seidel L, et al. Comparative in vitro activity of amphotericine B, itraconazole, voriconazole and posaconazole against Aspergillus fumigatus. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy: 381, 22 Sep 2001

  16. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. Journal of Clinical Microbiology 36: 2950–2956, Oct 1998

    PubMed  CAS  Google Scholar 

  17. Espinel-Ingroff A, Del Palacio A. A comparison of the in vitro activities of the new triazole SCH56592 with those of four established and investigational agents against dermatophytes and other moulds. Ninety-Ninth General Meeting American Society for Microbiology: 27, 30 May 1999

  18. Barchiesi F, Arzeni D, Fothergill AW, et al. In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens. Antimicrobial Agents and Chemotherapy 44: 226–229, Jan 2000

    Article  PubMed  CAS  Google Scholar 

  19. Cacciapuoti A, Loebenberg D, Corcoran E, et al. In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrobial Agents and Chemotherapy 44: 2017–2022, Aug 2000

    Article  PubMed  CAS  Google Scholar 

  20. Pfaller MA, Messer SA, Hollis RJ, et al. Antifungal activity of posaconazole, ravuconazole, and voriconazole compared to that of itraconazole tested against 213 clinical isolates of Aspergillus spp. and other filamentous fungi: report from the SENTRY Antimicrobial Surveillance Program, 2000. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy: 379 (plus poster), 22 Sep 2001

  21. Sun QN, Fothergill AW, McCarthy DI, et al. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrobial Agents and Chemotherapy 46: 1581–1582, May 2002

    Article  PubMed  CAS  Google Scholar 

  22. Mellinghoff I, Mukwaya G, Winston D, et al. Use of posaconazole (SCH56592) for treatment of invasive fungal infections refractory to standard antifungal therapy. Blood 96: 341, Part 2, 16 Nov 2000

    Google Scholar 

Download references

Author information

Consortia

Adis Editorial

Additional information

This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adis Editorial. Posaconazole. Drugs R&D 4, 258–263 (2003). https://doi.org/10.2165/00126839-200304040-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200304040-00009

Keywords

Search

Navigation